AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,235.50GBp
11:58am EDT
Price Change (% chg)

66.00p (+1.58%)
Prev Close
4,169.50p
Open
4,175.50p
Day's High
4,236.50p
Day's Low
4,141.00p
Volume
2,358,314
Avg. Vol
2,638,638
52-wk High
4,946.41p
52-wk Low
3,154.00p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments... (more)

Overall

Beta: 0.42
Market Cap (Mil.): £52,422.50
Shares Outstanding (Mil.): 1,262.75
Dividend: 53.10
Yield (%): 4.07

Financials

  AZN.L Industry Sector
P/E (TTM): 41.80 32.74 33.38
EPS (TTM): 0.99 -- --
ROI: 5.03 18.26 17.53
ROE: 8.94 18.93 18.34
Search Stocks

Banks could miss out on $135 million fees as Abbvie drops Shire deal

LONDON - A decision by U.S. drugmaker AbbVie to scrap its plans to buy Dublin-based Shire could mean that bankers miss out on up to $135 million in fees linked to the deal.

16 Oct 2014

Novartis psoriasis drug benefits outweighs risk-FDA staff

- The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said.

16 Oct 2014

UPDATE 1-Novartis psoriasis drug benefits outweighs risk-FDA staff

Oct 16 - The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said.

16 Oct 2014

AstraZeneca looks to EU decision for next cancer drug boost

LONDON - AstraZeneca's cancer drug pipeline, already on a roll following promising clinical trial results, could get a further boost next week from a European green light for an experimental medicine against ovarian cancer.

14 Oct 2014

AstraZeneca looks to EU decision for next cancer drug boost

LONDON - AstraZeneca's cancer drug pipeline, already on a roll following promising clinical trial results, could get a further boost next week from a European green light for an experimental medicine against ovarian cancer.

14 Oct 2014

AstraZeneca looks to EU decision for next cancer drug boost

* EU agency to decide on olaparib in ovarian cancer next week

14 Oct 2014

AstraZeneca heart drug gets preferred status in U.S.

LONDON, Oct 6 - AstraZeneca's blood-thinning drug Brilinta has won preferred status in the United States, where two medical groups have recommended it over the older drug Plavix, also known as clopidogrel.

06 Oct 2014

Becton Dickinson to buy CareFusion for $12 billion in cash, stock

- Medical equipment supplier Becton Dickinson & Co has agreed to buy CareFusion Corp , a maker of infusion pumps and other medical devices, for $12.2 billion in cash and stock, marking the latest multibillion-dollar healthcare sector deal.

05 Oct 2014

UPDATE 3-Becton Dickinson to buy CareFusion for $12 bln in cash, stock

Oct 5 - Medical equipment supplier Becton Dickinson & Co has agreed to buy CareFusion Corp , a maker of infusion pumps and other medical devices, for $12.2 billion in cash and stock, marking the latest multibillion-dollar healthcare sector deal.

05 Oct 2014

UPDATE 2-Ardelyx, AstraZeneca bowel drug succeeds in mid-stage trial

Oct 1 - Ardelyx Inc said its experimental drug to treat constipation-related irritable bowel syndrome achieved the main goal of increasing bowel movement compared with a placebo in a mid-stage study involving 371 patients.

01 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks